Published in Cardiovascular Week, October 22nd, 2007
Paclitaxel-eluting stents (PESs) are commonly used to delivery the drug directly to the wall of the coronary artery and limit the growth of scar within the stents. Paclitaxel is a microtubule-stabilizing agent also used in the treatment of ovarian and breast cancer and its principal adverse effect is a sensory neuropathy.
A 65-year old man presented with symmetric numbness in all his...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.